• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Atrion Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8/21/24 8:54:15 AM ET
    $ATRI
    Medical/Dental Instruments
    Health Care
    Get the next $ATRI alert in real time by email
    false --12-31 0000701288 0000701288 2024-08-21 2024-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K
    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

     

    Date of Report (Date of earliest event reported): August 21, 2024

     

    Atrion Corporation

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   001-32982   63-0821819
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    One Allentown Parkway

    Allen, Texas 75002

    (Address of principal executive offices) (Zip Code)

     

    (972) 390-9800

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of each class   Trading Symbol   Name of exchange on which registered
    Common Stock, $0.10 par value per share   ATRI   The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    INTRODUCTORY NOTE

     

    As previously disclosed in our Current Report on Form 8-K filed with the United States Securities and Exchange Commission (the “SEC”) on May 29, 2024, Atrion Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger, dated as of May 28, 2024 (the “Merger Agreement”), with Nordson Corporation, an Ohio corporation (“Parent”), and Alpha Medical Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).

     

    On August 21, 2024, the Company completed its merger with Merger Sub pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Company, in accordance with the Delaware General Corporation Law, as amended (the “DGCL”), with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent (the “Merger”).

     

    At the effective time of the Merger (the “Effective Time”):

     

    (i)each share of common stock, par value $0.10 per share, of the Company issued and outstanding immediately prior to the Effective Time (each, a “Share” and collectively, the “Shares”), other than Shares (a) held in the treasury of the Company or owned by any direct or indirect wholly owned subsidiary of the Company, (b) owned by Merger Sub, Parent or any direct or indirect wholly owned subsidiary of Parent or (c) held by holders or beneficial holders who (i) are entitled to demand appraisal rights under Section 262 of the DGCL, (ii) have properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and (iii) as of the Effective Time, have neither effectively waived, withdrawn nor lost their rights to such appraisal and payment under the DGCL (such Shares, “Dissenting Shares”), was automatically canceled and converted into the right to receive $460 in cash, without interest (the “Merger Consideration”); and

     

    (ii)each outstanding restricted stock unit award granted to an employee or non-employee service provider, whether stock-settled or cash-settled, whether settled on a current or a deferred basis, and whether or not granted pursuant to a Company stock plan (each, a “Company RSU”), whether vested but unsettled or unvested (including Company RSUs with market- or performance-based conditions (“Company PSUs”)), was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration and (b) the aggregate number of Shares underlying or denominated by such Company RSU (with respect to Company PSUs, vesting at target), less applicable taxes and authorized deductions.

     

    The foregoing description of the Merger Agreement and the transactions contemplated thereby contained in this Introductory Note does not purport to be complete, and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, which is incorporated as Exhibit 2.1 hereto by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company with the SEC on May 29, 2024.

     

    ITEM 1.02TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT.

     

    On August 21, 2024, in connection with the consummation of the Merger, the Company paid in full all outstanding indebtedness and all other amounts (except those obligations that expressly survive termination) under, and terminated, the Amended and Restated Credit Agreement, dated as of December 21, 2023, among the Company, as borrower, and Wells Fargo Bank, National Association, as lender (as amended, restated, amended and restated or otherwise modified from time to time, the “Credit Agreement”). Upon such termination, all rights, obligations (except those obligations that expressly survive the termination of the Credit Agreement), liabilities and security interests under the Credit Agreement were fully and unconditionally released and discharged.

     

     

     

     

    ITEM 2.01COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

     

    As described in the Introductory Note of this Current Report on Form 8-K, on August 21, 2024, the Merger was completed. Upon the consummation of the Merger, the Company became a wholly owned subsidiary of Parent. The disclosure under the Introductory Note to this Current Report on Form 8-K is incorporated herein by reference.

     

    ITEM 3.01NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.

     

    The disclosures under the Introductory Note of this Current Report on Form 8-K are incorporated herein by reference.

     

    On August 20, 2024, the Company requested that The Nasdaq Global Select Market (“Nasdaq”) halt trading of the Shares effective following closing of the after-market trading session on August 20, 2024.

     

    On August 21, 2024, the Company requested that Nasdaq (A) suspend trading of the Shares effective at the close of market on August 21, 2024 and (B) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to effect the delisting of the Shares from Nasdaq and to deregister the Shares under Section 12(b) of the Exchange Act. In addition, the Company intends to file with the SEC a Certification and Notice of Termination of Registration on Form 15 requesting that the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.

     

    ITEM 3.03MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS.

     

    The disclosures under the Introductory Note and Items 2.01, 3.01 and 5.03 of this Current Report on Form 8-K are incorporated herein by reference.

     

    At the Effective Time, each holder of Shares outstanding immediately prior to the Effective Time ceased to have any rights with respect to such Shares and as a stockholder of the Company, except (i) the right to receive the Merger Consideration in accordance with the Merger Agreement, or (ii) in the case of Dissenting Shares, the right to receive only the payment provided by Section 262 of the DGCL in respect of such Dissenting Shares.

     

    ITEM 5.01CHANGES IN CONTROL OF REGISTRANT.

     

    The disclosures under the Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K are incorporated herein by reference.

     

    As a result of the Merger, a change in control of the Company occurred, and the Company became a wholly owned subsidiary of Parent.

     

    ITEM 5.02DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

     

    The disclosures under the Introductory Note and Item 2.01 of this Current Report on Form 8-K are incorporated herein by reference.

     

    Pursuant to the Merger Agreement, as of the Effective Time, each of Preston G. Athey, Jeannette Bankes, Emile A Battat, Ronald N. Spaulding and John P. Stupp, Jr., comprising all of the members of the Company’s board of directors, ceased serving as a member of the Company’s board of directors and each committee thereof. Pursuant to the Merger Agreement, as of the Effective Time, each of Stephen Lovass and Jennifer L. McDonough, comprising all of the members of the board of directors of Merger Sub as of immediately prior to the Effective Time, became a member of, and collectively comprise the sole members of, the Company’s board of directors.

     

    As of immediately prior to the Effective Time, each of Emile A. Battat, David A. Battat and Cindy Ferguson, comprising all of the officers of the Company, resigned as officers of the Company. Pursuant to the Merger Agreement, as of the Effective Time, each of Stephen Lovass, Jennifer L. McDonough and Anand Patel, comprising all of the officers of Merger Sub as of immediately prior to the Effective Time, became an officer of, and collectively comprise the sole officers of, the Company.

     

    Each of Mr. David A. Battat and Mr. Emile A. Battat ceased employment with the Company effective immediately prior to the Effective Time. In connection with their separations from employment with the Company, each executive has entered into a separation agreement with the Company and Parent providing for the existing severance payments and benefits that such executive was entitled to receive under Section 3 of Mr. David A. Battat’s Second Amended and Restated Change in Control Agreement, filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed November 8, 2017, and Section 4(e)(ii) of Mr. Emile A. Battat’s Second Amended and Restated Employment Agreement, filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed May 8, 2019, respectively.

     

     

     

     

    ITEM 5.03AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE OF FISCAL YEAR.

     

    The disclosures under the Introductory Note and Item 2.01 of this Current Report on Form 8-K are incorporated herein by reference.

     

    Pursuant to the Merger Agreement, effective as of the Effective Time, the amended and restated certificate of incorporation of the Company and the amended and restated bylaws of the Company were each amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, which are incorporated herein by reference.

     

    ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS.

     

    (d) Exhibits.

     

    Exhibit No.   Description
       
    2.1   Agreement and Plan of Merger, dated as of May 28, 2024, by and among Nordson Corporation, Alpha Medical Merger Sub, Inc. and Atrion Corporation (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Atrion Corporation with the SEC on May 29, 2024).
       
    3.1   Amended and Restated Certificate of Incorporation of Atrion Corporation.
       
    3.2   Amended and Restated Bylaws of Atrion Corporation.
         
    104   Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

         
        ATRION CORPORATION
         
    Date:  August 21, 2024 By: /s/ Jennifer L. McDonough
        Jennifer L. McDonough
        Secretary

     

     

     

    Get the next $ATRI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATRI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATRI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Atrion Corporation

      15-12G - ATRION CORP (0000701288) (Filer)

      9/3/24 9:11:57 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:24:19 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:23:12 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Atrion Corporation Enters Into Merger Agreement with Nordson Corporation

      ALLEN, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrion's 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrion's 90-day average daily volume-weighted average stock price. The proposed transaction was unanimously approved by the Boards of Directors of Atrion

      5/28/24 7:24:38 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials

    $ATRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stupp John P Jr returned $69,149,960 worth of shares to the company (150,326 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 5:00:44 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Spaulding Ronald Nicholas returned $1,231,880 worth of shares to the company (2,678 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:30:30 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Athey Preston G returned $629,280 worth of shares to the company (1,368 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:19:38 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Athey Preston G bought $95,904 worth of shares (300 units at $319.68), increasing direct ownership by 28% to 1,368 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      12/1/23 2:53:55 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Battat David A bought $90,000 worth of shares (300 units at $300.00), increasing direct ownership by 0.77% to 39,400 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      11/16/23 2:49:33 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Financials

    Live finance-specific insights

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials
    • Atrion Corporation Declares Quarterly Cash Dividend

      ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy FergusonVice President and Chief Financial Officer(972) 390-9800         

      5/21/24 4:30:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atrion Corporation

      SC 13G/A - ATRION CORP (0000701288) (Subject)

      9/9/24 4:05:03 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:05:08 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:04:56 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care